Wedbush Weighs in on Verona Pharma plc’s FY2026 Earnings (NASDAQ:VRNA)

Verona Pharma plc (NASDAQ:VRNA) – Investment analysts at Wedbush dropped their FY2026 earnings estimates for shares of Verona Pharma in a report released on Thursday, November 2nd. Wedbush analyst A. Argyrides now expects that the company will post earnings of $0.59 per share for the year, down from their previous forecast of $0.73. Wedbush has a “Outperform” rating and a $33.00 price objective on the stock. The consensus estimate for Verona Pharma’s current full-year earnings is ($0.86) per share. Wedbush also issued estimates for Verona Pharma’s FY2027 earnings at $2.65 EPS.

VRNA has been the topic of several other reports. Canaccord Genuity Group reissued a “buy” rating and issued a $35.00 target price on shares of Verona Pharma in a report on Friday, September 1st. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of Verona Pharma in a report on Monday, September 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Verona Pharma currently has a consensus rating of “Buy” and a consensus price target of $32.60.

Verona Pharma Price Performance

VRNA stock opened at $15.37 on Monday. The company has a quick ratio of 26.29, a current ratio of 26.29 and a debt-to-equity ratio of 0.07. Verona Pharma has a 12 month low of $11.56 and a 12 month high of $26.44. The firm has a market cap of $9.77 billion, a P/E ratio of -22.28 and a beta of 0.28. The company’s 50-day moving average price is $16.06 and its two-hundred day moving average price is $19.10.

Verona Pharma (NASDAQ:VRNA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.16.

Insider Activity at Verona Pharma

In related news, insider Kathleen A. Rickard sold 58,752 shares of Verona Pharma stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $1.92, for a total transaction of $112,803.84. Following the sale, the insider now directly owns 2,840,640 shares of the company’s stock, valued at approximately $5,454,028.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Verona Pharma

A number of institutional investors have recently added to or reduced their stakes in VRNA. FMR LLC lifted its position in shares of Verona Pharma by 110.1% in the 1st quarter. FMR LLC now owns 4,567,179 shares of the company’s stock worth $91,709,000 after purchasing an additional 2,393,033 shares during the period. Fairmount Funds Management LLC lifted its position in shares of Verona Pharma by 8.8% during the 1st quarter. Fairmount Funds Management LLC now owns 3,127,429 shares of the company’s stock valued at $62,799,000 after acquiring an additional 251,903 shares during the period. Carlyle Group Inc. acquired a new position in shares of Verona Pharma during the 1st quarter valued at $49,347,000. Jennison Associates LLC lifted its position in shares of Verona Pharma by 3.9% during the 3rd quarter. Jennison Associates LLC now owns 1,442,566 shares of the company’s stock valued at $23,514,000 after acquiring an additional 53,903 shares during the period. Finally, Nicholas Investment Partners LP lifted its position in shares of Verona Pharma by 23.6% during the 2nd quarter. Nicholas Investment Partners LP now owns 1,163,355 shares of the company’s stock valued at $24,593,000 after acquiring an additional 222,055 shares during the period. 9.89% of the stock is owned by institutional investors.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.